How does lanreotide compare to octreotide?

Both are somatostatin analogs with similar efficacy. Lanreotide is given as deep subcutaneous injection every 4 weeks (Somatuline Depot) vs octreotide LAR intramuscularly every 4 weeks. Lanreotide's autogel formulation allows patient self-administration after training. Efficacy for NETs and acromegaly is comparable. Choice often depends on formulation preference, cost, and insurance coverage.

Can lanreotide shrink neuroendocrine tumors?

Lanreotide primarily stabilizes tumor growth rather than shrinking tumors. The CLARINET trial showed it prolonged progression-free survival by preventing tumor growth, with objective tumor shrinkage in a minority of patients (~10%). For tumor reduction, peptide receptor radionuclide therapy (PRRT) with lutetium-177 DOTATATE is more effective.

Treatment hubFDA ApprovedDeep Dive

Lanreotide Treatment Guide: Somatuline Depot, Cost and Provider Paths

In the United States, Lanreotide is an FDA-approved peptide therapy. Unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors; acromegaly

Published: Apr 27, 2026Updated: Apr 27, 2026Medically reviewed: Apr 27, 2026Current

Medically Reviewed

This content was medically reviewed by James Patterson, MD, Board-Certified in Sports Medicine and Physical Medicine & Rehabilitation.

Last reviewed: April 27, 2026

Overview

Lanreotide is a synthetic somatostatin analog approved by the FDA for gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and acromegaly. It is a long-acting depot formulation given every 4 weeks.

Approved Product Paths

Somatuline Depot

Branded lanreotide pathway. Unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors; acromegaly

Benefits

•First-line therapy for well-differentiated GEP-NETs (CLARINET trial)
•Prolongs progression-free survival in metastatic NETs
•Controls GH and IGF-1 in acromegaly
•Deep subcutaneous autogel formulation

Side Effects & Friction

•GI symptoms (diarrhea, nausea, abdominal pain)
•Gallstones and cholelithiasis (long-term use)
•Hyperglycemia
•Injection site reactions

Administration Routes

Subcutaneous injection

Cost Reality

Lanreotide costs vary by brand, pharmacy, and insurance design. As an FDA-approved medication, coverage may be available but often requires prior authorization and documentation of the approved indication.

Provider Path

The highest-value next step is finding a provider experienced in immune support who can evaluate whether Lanreotide fits the patient's clinical profile and insurance constraints.

How Lanreotide Works

Lanreotide is a synthetic somatostatin analog that binds preferentially to somatostatin receptor subtypes 2 and 5 (SSTR2, SSTR5). It suppresses growth hormone secretion, inhibits GI hormone release, and slows tumor growth in neuroendocrine tumors.

Lanreotide is an octapeptide somatostatin analog with high affinity for SSTR2 and SSTR5. Like octreotide, it suppresses GH release from the pituitary, making it effective for acromegaly.

In neuroendocrine tumors, lanreotide binds to SSTR2 on tumor cells, inhibiting hormone secretion and exerting antiproliferative effects. The CLARINET trial demonstrated progression-free survival benefit in gastrointestinal and pancreatic NETs.

The extended-release depot formulation (Somatuline Depot) uses biodegradable polymers to release drug over 4 weeks, allowing monthly deep subcutaneous administration.

Lanreotide also reduces splanchnic blood flow and inhibits GI secretions, similar to octreotide. This can be useful for symptomatic control in hormone-secreting tumors.

Compared to octreotide LAR, lanreotide autogel has a slightly different release profile and may be preferred by some patients due to the deep subcutaneous rather than intramuscular injection.

Lanreotide's antiproliferative effect in NETs is mediated through SSTR2-driven activation of phosphotyrosine phosphatases and inhibition of the PI3K/Akt/mTOR pathway in tumor cells.

Somatostatin receptor 2 (SSTR2)Somatostatin receptor 5 (SSTR5)Pituitary somatotrophsNET tumor cells

Clinical Trial Evidence

Acromegaly trials

PMID: 12371928

Population: Patients with active acromegaly

N= 149

Duration: 48 weeks

Endpoint: GH and IGF-1 normalization

GH <2.5 ng/mL in 54% of patients
IGF-1 normalization in 38%
Monthly dosing achieved biochemical control comparable to more frequent regimens

CLARINET (NET antiproliferative)

Population: Patients with well-differentiated GI or pancreatic NETs

N= 204

Duration: Median 96 weeks

Endpoint: Progression-free survival

Median PFS not reached vs 18.0 months placebo (HR 0.47, p<0.001)
Significant benefit in both GI and pancreatic NET subgroups
Well tolerated with manageable side effects

Dosing & Administration

Acromegaly (Somatuline Depot)Deep subcutaneous · Every 4 weeks

Starting: 90 mg every 4 weeks

Titration: May increase to 120 mg every 4 weeks if GH/IGF-1 not controlled

Maintenance: 90-120 mg every 4 weeks

Maximum: 120 mg every 4 weeks

•Administered by healthcare professional via deep subcutaneous injection into superior external quadrant of buttock
•Rotate sites between left and right buttock
•Monitor GH and IGF-1 every 3-6 months
•Short-acting octreotide may be used briefly after initiation if needed

GI/pancreatic NETs (Somatuline Depot)Deep subcutaneous · Every 4 weeks

Starting: 120 mg every 4 weeks

Titration: No titration within course

Maintenance: 120 mg every 4 weeks

Maximum: 120 mg every 4 weeks

•Same administration as acromegaly dose
•Monitor tumor imaging and markers every 3-6 months
•For breakthrough symptoms, short-acting rescue may be used

Side Effect Profile

Gastrointestinal

Diarrheamild26%

Common; usually mild

Abdominal painmild20%

Usually mild

Nauseamild15%

Transient

Metabolic

Cholelithiasismoderate20%

Long-term use; usually asymptomatic; ultrasound monitoring recommended

Hyperglycemiamoderate5%

Monitor glucose

Hypothyroidismmoderate2%

Monitor TSH

Injection site

Painmild5%

Deep SC injection discomfort

Contraindications & Warnings

Do Not Use

Hypersensitivity to lanreotide

Important Warnings

Gallbladder effects: increased gallstone risk with long-term use. Annual gallbladder ultrasound recommended.
Glucose dysregulation: may cause hyper- or hypoglycemia. Monitor blood glucose.
Bradycardia and conduction abnormalities: use caution in cardiac patients.
Thyroid function suppression: monitor TSH periodically.
Fat malabsorption and B12 deficiency possible with chronic use.

Drug Interactions

Drug	Interaction	Severity	Mechanism
Cyclosporine	Reduced absorption	major	May reduce cyclosporine levels; monitor
Bromocriptine	Increased bromocriptine levels	moderate	May increase bromocriptine bioavailability
Insulin/oral hypoglycemics	Glucose effects	moderate	May alter glucose control unpredictably

Monitoring Requirements

GH and IGF-1 every 3-6 months (acromegaly)
Gallbladder ultrasound annually
Fasting glucose periodically
Thyroid function annually
Tumor imaging every 3-6 months (NETs)

How Lanreotide Compares

EfficacyOctreotide LAR advantage

Lanreotide: Similar GH/IGF-1 control

Octreotide LAR: Similar

Both effective; choice often based on injection preference

InjectionOctreotide advantage

Lanreotide: Deep SC (buttock)

Octreotide: IM (gluteal)

Patient preference varies

NET antiproliferativeOctreotide advantage

Lanreotide: CLARINET: PFS HR 0.47

Octreotide: PROMID: PFS HR 0.34

Both demonstrate antiproliferative benefit in different NET populations

IGF-1 normalizationPegvisomant advantage

Lanreotide: ~38%

Pegvisomant: ~90%

Pegvisomant more effective for IGF-1 but is GH receptor antagonist, not suppressant

Evidence Quality Assessment

Overall Evidence Grade: A

A = Strong evidence from multiple large RCTs

Human RCTs: Extensive: Acromegaly trials, CLARINET NET trial

Long-term data: Good: CLARINET long-term follow-up; decades of acromegaly use

Real-world evidence: Extensive: Standard of care alternative to octreotide

Regulatory status: FDA-approved for acromegaly and GI/pancreatic neuroendocrine tumors

Is Lanreotide Right for You?

Ideal Candidates

Acromegaly patients who prefer deep SC over IM injection
GI or pancreatic NET patients requiring antiproliferative therapy
Patients with SSTR2-positive tumors and hormone secretion symptoms

Avoid

Patients requiring maximum GH suppression (pegvisomant may be needed)
SSTR2-negative tumors
Uncontrolled diabetes

Use With Caution

Diabetes
Gallbladder disease
Cardiac disease
Thyroid disease

Cost & Insurance Deep Dive

List Price (Monthly)

~$4,000-$5,000/month

Cash-Pay Range

$3,500-$5,000/month

Insurance Coverage Rate

~80-90% for approved indications

Prior Auth Likelihood

High; requires diagnosis confirmation

Savings Programs

Ipsen patient assistanceFree for eligible patients

Eligibility: Uninsured, income ≤400% FPL

Annual application

Copay assistanceMay reduce out-of-pocket

Eligibility: Commercially insured

Not for government insurance

Cost-Effectiveness Notes

•Comparable to octreotide in cost and efficacy
•CLARINET data supports use in NETs where progression delay has clinical value
•No generic available

Ready to find a lanreotide provider?

Use the provider matcher to compare treatment paths by state, coverage, budget, urgency, and intake mode before committing to a prescribing workflow.

Find a lanreotide provider

Progress Tracking Tools

Monitor health markers and outcomes during treatment.

Smart WiFi Body Scale

Tracks BMI, body fat %, and muscle mass — essential for monitoring GLP-1 progress over time.

$30–60View on Amazon

Digital Kitchen Food Scale

Precise gram-level portion tracking helps maximize weight loss results on GLP-1 therapy.

$10–20View on Amazon

Protein Shaker Bottle Set

Leak-proof mixing bottles for protein shakes — supports consistent protein intake on a smaller appetite.

$12–25View on Amazon

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.

Lanreotide FAQ

Sources

1. Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
N Engl J Med • 2014
Claim type: clinical
View source →
2. FDA Information on Lanreotide
FDA • 2026
Claim type: regulatory
View source →

This content is for informational purposes only and does not constitute medical advice.